Intelerad Acquires PenRad Technologies, Inc., Expanding Breast Imaging and Lung Screening Capabilities
Summary
The acquisition will expand Intelerad’s product offerings for mammography and lung analytics, optimizing workflows for radiologists and boosting health outcomes for patients. Founded in 1995, PenRad’s three core product offerings – PenRad for breast imaging, PenLung for lung screening, and PenTrac for patient tracking and reporting – have a proven track record of eliminating overhead costs, decreasing liability exposure and increasing patient satisfaction for innovative enterprise systems and diagnostic imaging centers and facilities. Cancer screenings, and most notably, mammograms, drastically decreased during the COVID-19 pandemic as many healthcare facilities were temporarily closed and others faced severe staffing shortages. By integrating PenRad’s core solutions into our company, we can ensure all patients have access to the scans they need to decrease health risks, while at the same time offering healthcare systems greater productivity.” This acquisition follows Intelerad’s recent investment by TA Associates. These include HL7 workgroups, Clinical Interoperability Modeling Initiative (CIMI), and the Cancer-Interoperability project supported by the ONC, FDA, CDC, NCI, NIH and RSNA.
Classifications
AskAI Classifications
LabelsLinked Companies
